Insulet (NSDQ:PODD) shareholders have agreed to settle a lawsuit alleging that the device-maker misrepresented the success of its Omnipod Eros roll-out in 2013.
The financial details of the settlement were undisclosed, but it includes $425,000 in attorney fees and an array of corporate compliance enhancements that Insulet plans to adopt.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet settles shareholder suit over Omnipod Eros device appeared first on MassDevice.